Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone

American Journal of Physiology - Renal Physiology

Volumn 293, Issue 1, 2007, Pages

  Mejía Vilet, Juan M ^a,b   Ramírez, Victoria ^a,b   Cruz, Cristino ^a,b   Uribe, Norma ^b   Gamba, Gerardo ^a,b   Bobadilla, Norma A ^a,b,c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c Unidad de Fisiologia Molecular   (Mexico)

Author keywords

Apoptosis; Endothelial nitric oxide synthase; Lipoperoxidation

Indexed keywords

MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE; ALDOSTERONE; ALDOSTERONE ANTAGONIST; CATALASE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; RNA; SUPEROXIDE DISMUTASE;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY TUBULE DISORDER; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR BLOCKING; RENAL PROTECTION; REPERFUSION INJURY; UPREGULATION; URINARY EXCRETION; ANIMAL; BIOSYNTHESIS; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; METABOLISM; NICK END LABELING; PATHOLOGY; PHYSIOLOGY; VASOCONSTRICTION; WESTERN BLOTTING; WISTAR RAT;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; BLOTTING, WESTERN; CATALASE; GLUTATHIONE PEROXIDASE; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KIDNEY DISEASES; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; RATS; RATS, WISTAR; RECEPTORS, MINERALOCORTICOID; REPERFUSION INJURY; RNA; SPIRONOLACTONE; SUPEROXIDE DISMUTASE; VASOCONSTRICTION;

EID: 34548012161     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00077.2007     Document Type: Article

References (51)

1. Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F, Takeuchi K, Ito S. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 14: 2255-2263, 2003.
2. Bobadilla NA, Tapia E, Franco M, Lopez P, Mendoza S, Garcia-Torres R, Alvarado JA, Herrera-Acosta J. Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int 46: 773-779, 1994.
3. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 14: 235-241, 2005.
4. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 1: 256-262, 2006.
5. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345: 925-926, 2001.
6. Daemen MA, vant'Veer C, Denecker G, Heemskerk VH, Wolfs TG, Clauss M, Vandenabeele P, Buurman WA. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 104: 541-549, 1999.
7. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 44: 135-141, 1987.
8. Feria I, Pichardo I, Juarez P, Ramirez V, Gonzalez MA, Uribe N, Garcia-Torres R, Lopez-Casillas F, Gamba G, Bobadilla NA. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 63: 43-52, 2003.
9. Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, Shagdarsuren E, Breu V, Haller H, Luft FC. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 37: 787-793, 2001.
10. Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int 66: 486-491, 2004.
11. Goligorsky MS, Brodsky SV, Noiri E. NO bioavailability, endothelial dysfunction, and acute renal failure: new insights into pathophysiology. Semin Nephrol 24: 316-323, 2004.
12. Gros R, Ding Q, Armstrong S, O'Neil C, Pickering JG, Feldman RD. Rapid effects of aldosterone on clonal human vascular smooth muscle cells. Am J Physiol Cell Physiol 292: C788-C794, 2007.
13. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, Han KH, Kim HK, Kang YS, Han JY, Kim YS, Cha DR. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17: 1362-1372, 2006.
14. Henry RJ, Sobel C, Segalove M. Turbidimetric determination of proteins with sulfosalicylic and trichloroacetic acid. Proc Soc Exp Biol Med 92: 748-751, 1956.
15. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 66: 1-9, 2004.
16. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol 14: 2395-2401, 2003.
17. Jassem W, Heaton ND. The role of mitochondria in ischemia/reperfusion injury in organ transplantation. Kidney Int 66: 514-517, 2004.
18. Jo SK, Yun SY, Chang KH, Cha DR, Cho WY, Kim HK, Won NH. alpha-MSH decreases apoptosis in ischaemic acute renal failure in rats: possible mechanism of this beneficial effect. Nephrol Dial Transplant 16: 1583-1591, 2001.
19. Joffe HV, Adler GK. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 10: 31-37, 2005.
20. Kaushal GP, Basnakian AG, Shah SV. Apoptotic pathways in ischemic acute renal failure. Kidney Int 66: 500-506, 2004.
21. Kelly KJ. Acute renal failure: much more than a kidney disease. Semin Nephrol 26: 105-113, 2006.
22. Kelly KJ, Molitoris BA. Acute renal failure in the new millennium: time to consider combination therapy. Semin Nephrol 20: 4-19, 2000.
23. Leopold JA, Dam A, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo JL. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 13: 189-197, 2007.
24. -ΔΔCT method. Methods 25: 402-408, 2001.
25. McAuley FT, Whiting PH, Thomson AW, Simpson JG. The influence of enalapril or spironolactone on experimental cyclosporin nephrotoxicity. Biochem Pharmacol 36: 699-703, 1987.
26. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, Kimura S, Yukimura T, Kiyomoto H, Kohno M, Abe Y, Nishiyama A. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16: 2906-2912, 2005.
27. Molitoris BA, Sutton TA. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int 66: 496-499, 2004.
28. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, Hirata Y, Naruse M. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 48: 165-171, 2006.
29. Ngarmukos C, Grekin RJ. Nontraditional aspects of aldosterone physiology. Am J Physiol Endocrinol Metab 281: E1122-E1127, 2001.
30. Nishiyama A, Abe Y. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. J Pharmacol Sci 100: 9-16, 2006.
31. Perez-Rojas J, Blanco JA, Cruz C, Trujillo J, Vaidya VS, Uribe N, Bonventre JV, Gamba G, Bobadilla NA. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 292: F131-F139, 2007.
32. Perez-Rojas JM, Derive S, Blanco JA, Cruz C, Martinez de la Maza L, Gamba G, Bobadilla NA. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 289: F1020-F1030, 2005.
33. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003.
34. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
35. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 33: 981-986, 1999.
36. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31: 451-458, 1998.
37. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232-237, 1999.
38. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 3871-3878, 2000.
39. Rude MK, Duhaney TA, Kuster GM, Judge S, Heo J, Colucci WS, Siwik DA, Sam F. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension 46: 555-561, 2005.
40. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
41. Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 114: 5-14, 2004.
42. Sessa WC. eNOS at a glance. J Cell Sci 117: 2427-2429, 2004.
43. Singh D, Chander V, Chopra K. Protective effect of catechin on ischemia-reperfusion-induced renal injury in rats. Pharmacol Rep 57: 70-76, 2005.
44. Trachtman H, Weiser AC, Valderrama E, Morgado M, Palmer LS. Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J Urol 172: 1590-1594, 2004.
45. Tumlin JA, Lea JP, Swanson CE, Smith CL, Edge SS, Someren JS. Aldosterone and dexamethasone stimulate calcineurin activity through a transcription-independent mechanism involving steroid receptor- associated heat shock proteins. J Clin Invest 99: 1217-1223, 1997.
46. Versteilen AM, Korstjens IJ, Musters RJ, Groeneveld AB, Sipkema P. Rho kinase regulates renal blood flow by modulating eNOS activity in ischemia-reperfusion of the rat kidney. Am J Physiol Renal Physiol 291: F606-F611, 2006.
47. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40: 504-510, 2002.
48. Weight SC, Bell PR, Nicholson ML. Renal ischaemia-reperfusion injury. Br J Surg 83: 162-170, 1996.
49. Wellwood JM, Price RG, Ellis BG, Thompson AE. A note on the practical aspects of the assay of N-acetyl-beta-glucosaminidase in human urine. Clin Chim Acta 69: 85-91, 1976.
50. Wijsman JH, Jonker RR, Keijzer R, van de Velde CJ, Cornelisse CJ, van Dierendonck JH. A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. J Histochem Cytochem 41: 7-12, 1993.
51. Yamasowa H, Shimizu S, Inoue T, Takaoka M, Matsumura Y. Endothelial nitric oxide contributes to the renal protective effects of ischemic preconditioning. J Pharmacol Exp Ther 312: 153-159, 2005.